Use of gyrase resistance mutants to guide selection of 8-methoxy- quinazoline-2,4-diones

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 11, 2008, Pages 3915-3921

  German, Nadezhda ^a   Malik, Muhammad ^b   Rosen, Jonathan D ^a   Drlica, Karl ^b   Kerns, Robert J ^a  

^a UNIVERSITY OF IOWA   (United States)

^b PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 CYCLOPROPYL 7 (3 ETHYL 1 PIPERAZINYL) 6 FLUORO 1,4 DIHYDRO 8 METHOXY 4 OXO 3 QUINOLINECARBOXYLIC ACID; 1 CYCLOPROPYL 8 METHOXYQUINAZOLINE 2,4 DIONE DERIVATIVE; 8 METHOXYQUINAZOLINE 2,4 DIONE DERIVATIVE; BICYCLO COMPOUND; CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE (ATP HYDROLYSING) A; MOXIFLOXACIN; PYRROLIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BACTERIAL STRAIN; BACTERIOSTASIS; CONTROLLED STUDY; DRUG STRUCTURE; DRUG SYNTHESIS; ESCHERICHIA COLI; GENE MUTATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; WILD TYPE;

ANTI-BACTERIAL AGENTS; DNA GYRASE; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; FLUOROQUINOLONES; GENES, BACTERIAL; HUMANS; MUTATION; QUINAZOLINONES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 55849113010     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00330-08     Document Type: Article

References (43)

1. Beylin, V., D. C. Boyles, T. T. Curran, D. Mackenas, R. V. Parlett, and D. Vrieze. 2007. The preparation of two, preclinical amino-quinazolinediones as antibacterial agents. Org. Proc. Res. Dev. 11:441-449.
2. Bird, P., E. Ellsworth, D. Nguyen, J. Sanchez, H. Showalter, R. Singh, M. Stier, T. Tran, B. Watson, and J. Yip. 2006. 3-Aminoquinazolin-2,4-dione antibacterial agents. U.S. patent 7,094,780 B1.
3. Domagala, J., S. Hagen, T. Joannides, J. Kiely, E. Laborde, M. Schroeder, J. Sesnie, M. Shapiro, M. Suto, and S. Vanderroest. 1993. Quinolone antibacterials containing the new 7-[3-(1-aminoethyl)-1-pyrrolidinyl] side chain: the effects of the 1-aminoethyl moiety and its stereochemical configurations on potency and in vivo efficiency. J. Med. Chem. 36:871-882.
4. Dong, Y., C. Xu, X. Zhao, J. Domagala, and K. Drlica. 1998. Fluoroquinolone action against mycobacteria: effects of C8 substituents on bacterial growth, survival, and resistance. Antimicrob. Agents Chemother. 42:2978-2984.
5. Dong, Y., X. Zhao, J. Domagala, and K. Drlica. 1999. Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus. Antimicrob. Agents Chemother. 43:1756-1758.
6. Ellsworth, E., T. Tran, H. H. Showalter, J. Sanchez, B. Watson, M. Stier, J. Domagala, S. Gracheck, E. Joannides, M. Shapiro, S. Dunham, D. Hanna, M. Huband, J. Gage, J. Bronstein, J. Liu, D. Nguyen, and R. Singh. 2006. 3-aminoquinazolinediones as a new class of antibacterial agents demonstrating excellent antibacterial activity against wild-type and multidrug resistant organisms. J. Med. Chem. 49:6435-6438.
7. Huband, M. D., M. A. Cohen, M. Zurack, D. L. Hanna, L. A. Skerlos, M. C. Sulavik, G. W. Gibson, J. W. Gage, E. Ellsworth, M. A. Stier, and S. J. Gracheck. 2007. In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. Antimicrob. Agents Chemother. 51:1191-1201.
8. Ince, D., X. Zhang, L. C. Silver, and D. C. Hooper. 2002. Dual targeting of DNA gyrase and topoisomerase IV: target interactions of garenoxacin (BMS-284756, T-3811ME), a new desfluoroquinolone. Antimicrob. Agents Chemother. 46:3370-3380.
9. Ito, T., M. Matsumoto, and T. Nishino. 1995. Improved bactericidal activity of Q.-35 against quinolone-resistant staphylococci. Antimicrob. Agents Chemother. 39:1522-1525.
10. Kimura, Y., S. Atarashi, M. Takahashi, and I. Hayakawa. 1994. Synthesis and structure-activity-relationships of 7-[3-(1-aminoalkyl) pyrrolidinyl]quinolone and 7-[3-(1-aminocycloalkyl)pyrrolidinyl]quinolone antibacterials. Chem. Pharm. Bull. 42:1442-1454.
11. Li, X., N. Mariano, J. J. Rahal, C. M. Urban, and K. Drlica. 2004. Quinolone-resistant Haemophilus influenzae in a long-term care facility: nucleotide sequence characterization of alterations in the genes encoding DNA gyrase and DNA topoisomerase IV. Antimicrob. Agents Chemother. 48:3570-3572.
12. Li, X., X. Zhao, and K. Drlica. 2002. Selection of Streptococcus pneumoniae mutants having reduced susceptibility to levofloxacin and moxifloxacin. Antimicrob. Agents Chemother. 46:522-524.
13. Liu, Y., J. Cui, R. Wang, X. Wang, K. Drlica, and X. Zhao. 2005. Selection of rifampicin-resistant Staphylococcus aureus during tuberculosis therapy: concurrent bacterial eradication and acquisition of resistance. J. Antimicrob. Chemother. 56:1172-1175.
14. Lu, T., X. Zhao, and K. Drlica. 1999. Gatifloxacin activity against quinolone-resistant gyrase: allele-specific enhancement of bacteriostatic and bactericidal activity by the C-8-methoxy group. Antimicrob. Agents Chemother. 43:2969-2974.
15. Lu, T., X. Zhao, X. Li, A. Drlica-Wagner, J.-Y. Wang, J. Domagala, and K. Drlica. 2001. Enhancement of fluoroquinolone activity by C-8 halogen and methoxy moieties: action against a gyrase resistance mutant of Mycobacterium smegmatis and a gyrase-topoisomerase IV double mutant of Staphylococcus aureus. Antimicrob. Agents Chemother. 45:2703-2709.
16. Malik, M., and K. Drlica. 2006. Moxifloxacin lethality with Mycobacterium tuberculosis in the presence or absence of chloramphenicol. Antimicrob. Agents Chemother. 50:2842-2844.
17. Malik, M., T. Lu, X. Zhao, A. Singh, C. Hattan, J. Domagala, R. Kerns, and K. Drlica. 2005. Lethality of quinolones against Mycobacterium smegmatis in the presence or absence of chloramphenicol. Antimicrob. Agents Chemother. 49:2008-2014.
18. Miller, J. 1972. Experiments in molecular genetics. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
19. Murphy, S., H. Case, E. Ellsworth, S. Hagen, M. Huband, T. Joannides, C. Limberakis, K. Marotti, A. Ottolini, M. Rauckhorst, J. Starr, M. Stier, C. Taylor, T. Zhu, A. Blaser, W. Denny, G. Lu, J. Smaill, and F. Rivault. 2007. The synthesis and biological evaluation of novel series of nitrile-containing fluoroquinolones as antibacterial agents. Bioorg. Med. Chem. Lett. 17:2150-2155.
20. Nakamura, S., M. Nakamura, T. Kojima, and H. Yoshida. 1989. gyrA and gyrB mutations in quinolone-resistant strains of Escherichia coli. Antimicrob. Agents Chemother. 33:254-255.
21. Nazir, J., C. Urban, N. Mariano, J. Burns, B. Tommasulo, C. Rosenberg, S. Segal-Maurer, and J. Rahal. 2004. Quinolone-resistant Haemophilus influenzae in a long-term care facility: clinical and molecular epidemiology. Clin. Infect. Dis. 38:1564-1569.
22. Ng, E. Y., M. Trucksis, and D. C. Hooper. 1996. Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus. Antimicrob. Agents Chemother. 40:1881-1888.
23. Okumura, R., T. Hirata, Y. Onodera, K. Hoshino, T. Otani, and T. Yamamoto. 2008. Dual-targeting properties of the 3-aminopyrrolidyl quinolones, DC-159a and sitafloxacin, against DNA gyrase and topoisomerase IV: contribution to reducing in vitro emergence of quinolone-resistant Streptococcus pneumoniae. J. Antimicrob. Chemother. 62:98-104.
24. Pan, X., and L. M. Fisher. 1998. DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 42:2810-2816.
25. Pan, X.-S., J. Ambler, S. Mehtar, and L. M. Fisher. 1996. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 40:2321-2326.
26. Pruss, G., R. Franco, S. Chevalier, S. Manes, and K. Drlica. 1986. Effects of DNA gyrase inhibitors in Escherichia coli topoisomerase I mutants. J. Bacteriol. 168:276-282.
27. Sanchez, J., R. Gogliotti, J. Domagala, S. Gracheck, M. Huband, J. Sesnie, M. Cohen, and M. Shapiro. 1995. The synthesis, structure-activity, and structure-side effect relationships of a series of 8-alkoxy- and 5-amino-8-alkoxyquinolone antibacterial agents. J. Med. Chem. 38:4478-4487.
28. Sindelar, G., X. Zhao, A. Liew, Y. Dong, J. Zhou, J. Domagala, and K. Drlica. 2000. Mutant prevention concentration as a measure of fluoroquinolone potency against mycobacteria. Antimicrob. Agents Chemother. 44:3337-3343.
29. Sternglanz, R., S. DiNardo, K. A. Voelkel, Y. Nishimura, Y. Hirota, A. K. Becherer, L. Zumstein, and J. C. Wang. 1981. Mutations in the gene coding for Escherichia coli DNA topoisomerase I affecting transcription and transposition. Proc. Natl. Acad. Sci. USA 78:2747-2751.
30. Strahilevitz, J., and D. C. Hooper. 2005. Dual targeting of topoisomerase IV and gyrase to reduce mutant selection: direct testing of the paradigm by using WCK-1734, a new fluoroquinolone, and ciprofloxacin. Antimicrob. Agents Chemother. 49:1949-1956.
31. Takei, M., H. Fukuda, R. Kishi, and M. Hosaka. 2001. Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition. Antimicrob. Agents Chemother. 45:3544-3547.
32. Tran, T., E. Ellsworth, J. Sanchez, B. Watson, M. Stier, H. Showalter, J. Domagala, M. Shapiro, E. Joannides, S. Gracheck, D. Nguyen, P. Bird, J. Yip, A. Sharadendu, C. Ha, S. Ramezani, X. Wu, and R. Singh. 2007. Structure-activity relationships of 3-aminoquinazolinediones, a new class of bacterial type-2 topoisomerase (DNA gyrase and topo IV) inhibitors. Bioorg. Med. Chem. Lett. 17:1312-1320.
33. Tran, T., E. Ellsworth, B. Watson, J. Sanchez, H. Showalter, J. Rubin, M. Stier, J. Yip, D. Nguyen, P. Bird, and R. Singy. 2005. Facile synthesis of substituted 3-amino-1H-quinazoline-2,4-diones. J. Heterocyclic Chem. 42:669-674.
34. Wall, J. D., and P. D. Harriman. 1974. Phage P1 mutants with altered transducing abilities for Escherichia coli. Virology 59:532-544.
35. Wehbeh, W., R. Rojas-Diaz, X. Li, N. Mariano, L. Grenner, S. Segal-Maurer, B. Tommasulo, K. Drlica, C. Urban, and J. Rahal. 2005. Fluoroquinolone-resistant Streptococcus agalactiae: epidemiology and mechanism of resistance. Antimicrob. Agents Chemother. 49:2495-2497.
36. Weinstock, H., J. Papp, and D. Trees. 2008. Antimicrobial resistance to sexually transmitted infections, p. 77-96. In I. Fong and K. Drlica (ed.), Antimicrobial resistance and implications for the 21st century. Springer Science and Business Media, New York, NY.
37. Yamagishi, J., H. Yoshida, M. Yamayoshi, and S. Nakamura. 1986. Nalidixic acid-resistant mutations of the gyrB gene of Escherichia coli. Mol. Gen. Genet. 204:367-373.
38. Yoshida, H., M. Bogaki, M. Nakamura, L. Yamanaka, and S. Nakamura. 1991. Quinolone resistance-determining region in the DNA gyrase gyrB gene of Escherichia coli. Antimicrob. Agents Chemother. 35:1647-1650.
39. Yoshida, T., Y. Yamamoto, H. Orita, M. Kakiuchi, Y. Takahashi, M. Itakura, N. Kado, K. Mitani, S. Yasuda, H. Kato, and Y. Itoh. 1996. Studies on quinolone antibacterials. IV. Structure-activity relationships of antibacterial activity and side effects for 5- or 8-substituted and 5,8-disubstituted-7-(3-amino-1-pyrrolidinyl)-1-cyclopropyl-1, 4-dihydro-4-oxoquinoline-3-carboxylic acids. Chem. Pharm. Bull. 44:1074-1085.
40. Zhao, X., and K. Drlica. 2001. Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies. Clin. Infect. Dis. 33(Suppl. 3):S147-S156.
41. Zhao, X., and K. Drlica. 2002. Restricting the selection of antibiotic-resistant mutants: measurement and potential uses of the mutant selection window. J. Infect. Dis. 185:561-565.
42. Zhao, X., C. Xu, J. Domagala, and K. Drlica. 1997. DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance. Proc. Natl. Acad. Sci. USA 94:13991-13996.
43. Zhou, J., Y. Dong, X. Zhao, S. Lee, A. Amin, S. Ramaswamy, J. Domagala, J. M. Musser, and K. Drlica. 2000. Selection of antibiotic resistant bacterial mutants: allelic diversity among fluoroquinolone-resistant mutations. J. Infect. Dis. 182:517-525.